edoc-vmtest

Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates

Joerger, M. and Templeton, A. and Köberle, D. and Engler, H. and Riesen, W. F. and Thürlimann, B.. (2011) Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer chemotherapy and pharmacology, Vol. 67, H. 5. pp. 1137-1144.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6004701

Downloads: Statistics Overview

Abstract

There is an urgent need for individualized treatment of malignant bone disease (MBD), as the clinical benefit from bone-targeted therapies is moderate. We assessed the predictive value of the bone formation marker procollagen type I N-propeptide (PINP) for skeletal morbidity in patients with MBD receiving pamidronate.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Onkologie
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Onkologie
UniBasel Contributors:Thürlimann, Beat
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Springer
ISSN:0344-5704
Note:Publication type according to Uni Basel Research Database: Journal article
Last Modified:27 Mar 2014 13:13
Deposited On:27 Mar 2014 13:13

Repository Staff Only: item control page